1. ALLA AKTIER
  2. NYHETER
  3. LUMITO

Lumito

Nyheter Lumito Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Lumito invites to a webinar in connection with the publication of its second-quarter 2026 report

MARKN.

On August 20, 2026, Lumito AB (publ) (“Lumito” or the “Company”) will publish its report for the second quarter of 2026. In connection with the publication, shareholders, investors and other interested parties are invited to a webinar on the same day at 11:00 a.m.

During the presentation, Sanna Wallenborg, CEO, will provide a brief introduction to Lumito and summarise the key events during the quarter. This will be followed by a presentation of the financial results for the period. Finally, questions submitted in advance to ir@lumito.se will be answered by Sanna Wallenborg and CFO Fata Mrsic.

The presentation and Q&A session will be recorded and made available on the Company’s website afterwards.

Date and time: 20 August 2026, at 11:00 a.m.
Registration for the webinar: https://events.teams.microsoft.com/event/c107d51a-e701-4013-8133-dda22acf3bb0@93b12032-4992-4d22-8a2c-445707f886f0?source=copyLinkLegacyShareEventDialog

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Growth Market under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
Lumito invites to a webinar in connection with the publication of its second-quarter 2026 report

Datum 2026-08-18, kl 11:00
Källa MFN
Bifogade filer
Lumito invites to a webinar in connection with the publication of its second-quarter 2026 report